Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 10/20 | 0.36 |
| ▸ | BTK | Q06187 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7866935 | 0.95 | PIK3CA (0.43) | PIK3CAGPR142ABCB1BTKHPGD | |
| SCHEMBL7865287 | 0.94 | HPGD (0.43) | PIK3CAGPR142ABCB1BTKHPGD | |
| SCHEMBL7871221 | 0.86 | HSD11B1 (0.40) | PIK3CAGPR142ABCB1HPGD | |
| SCHEMBL3755587 | 0.85 | PIK3CA (0.58) | PIK3CAGPR142 | |
| SCHEMBL7869391 | 0.85 | ABCB1 (0.41) | PIK3CAABCB1HPGDHRH4 | |
| SCHEMBL7866556 | 0.85 | SPR (0.44) | PIK3CAABCB1HRH4 | |
| SCHEMBL7870080 | 0.83 | GPR142 (0.47) | PIK3CAGPR142ABCB1BTKHPGD | |
| SCHEMBL7868242 | 0.83 | PIK3CA (0.47) | PIK3CAABCB1PARP1 | |
| SCHEMBL7871184 | 0.83 | HTT (0.49) | PIK3CAABCB1HPGD | |
| SCHEMBL7867794 | 0.83 | PIK3CA (0.40) | PIK3CAGPR142ABCB1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | MTOR, RICTOR, RPTOR | PIK3CA 16/4885GPR142 4122/4885ABCB1 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.